December 08, 2006 Sanofi-aventis announces that concerning the New Drug Application for rimonabant in the United States, the Food and Drug Administration has considered its October 26, 2006 resubmission to be a complete, class 2 response to the FDA February 17, 2006 action letter. The user fee goal date is April 26, 2007. Rimonabant is a first-in-class cannabinoid type 1 (CB1) receptor blocker discovered and developed by Sanofi-Aventis. 27kg/m2) with associated risk factors, such as type 2 diabetes or dyslipidaemia. Rimonabant is currently commercialized in the United Kingdom, Germany, Denmark, Sweden, Finland, Norway, Ireland, Argentina and Austria. Read the complete news article here: http://biz.yahoo.com/prnews/061208/nyf018.html?.v=72